A TLR7 agonist
Related Products
Labeled Version(s)
26424Imiquimod-d9
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Imiquimod

Item No. 14956

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine
CAS Number
99011-02-6
Synonyms
  • R-837
  • S-26308
  • TMX 101
Molecular Formula
C14H16N4
Formula Weight
240.3
Purity
≥95%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 1 mg/mlDMSO: 1 mg/ml
λmax
240, 246, 267, 326 nm
SMILES
NC1=NC2=C(C3=C1N=CN3CC(C)C)C=CC=C2
InChi Code
InChI=1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17)
InChi Key
DOUYETYNHWVLEO-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    100 mg

    $43

    Add

    250 mg

    $81

    Add

    500 mg

    $151

    Add

    1 g

    $258

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Imiquimod is an imidazoquinoline agonist of toll-like receptor 7 (TLR7; EC50 = 2.12 μM).1 It increases TNF-α and IL-12 p40 production in IFN-γ-treated murine peritoneal macrophages in a concentration- and MyD88-dependent manner.2 Topical application of imiquimod (30 μl of 5% cream) increases TNF and IFN levels at the application site in hairless mice.3 Imiquimod dose-dependently increases serum levels of IFN-α in mice when administered by gavage.4 It reduces tumor growth in an MC-26 model of murine colon cancer when administered at a dose of 30 mg/kg every three days. Imiquimod (5 mg/kg, intravaginally, twice daily) reduces vaginal viral titer and lesion formation in a guinea pig model of genital HSV-2 infection.5 Formulations containing imiquimod have been used in the treatment of actinic keratosis, superficial basal cell carcinoma, and external genital warts.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Shukla, N.M., Mallardi, S.S., Mutz, C.A., et al. Structure-activity relationships in human toll-like receptor 7-active imidazoquinoline analogues. J. Med. Chem. 53(11), 4450-4465 (2010).

    2. Hemmi, H., Kaisho, T., Takeuchi, O., et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3(2), 196-200 (2002).

    3. Imbertson, L.M., Beaurline, J.M., Couture, A.M., et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J. Invest. Dermatol. 110(5), 734-739 (1998).

    4. Sidky, Y.A., Borden, E.C., Weeks, C.E., et al. Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res. 52(13), 3528-3533 (1992).

    5. Harrison, C.J., Jenski, L.J., Voychehovski, T., et al. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antiviral Res. 10(4-5), 209-223 (1988).

    Product Citations

    Sivasami, P., Elkins, C., Diaz-Saldana, P.P., et al. Obesity-induced dysregulation of skin-resident PPARγ+ Treg cells promotes IL-17A-mediated psoriatic inflammation. Immunity 56(8), 1844-1861 (2023).